Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Neoplasms 53%
3. Transforming Growth Factors 34%
4. ErbB Receptors 31%
5. Trastuzumab 25%
6. Phosphatidylinositol 3-Kinase 25%
7. Protein-Tyrosine Kinases 22%
8. Estrogen Receptors 22%
9. Breast 18%
10. Mutation 18%
11. Phosphatidylinositol 3-Kinases 17%
12. Therapeutics 17%
13. Early Detection of Cancer 16%
14. human ERBB2 protein 15%
15. Growth 15%
16. Phosphotransferases 15%
17. Estrogen Receptor Modulators 15%
18. Colorectal Neoplasms 15%
19. Lapatinib 14%
20. Letrozole 14%
21. Estrogens 13%
22. Triple Negative Breast Neoplasms 13%
23. Ligands 13%
24. Rhabdomyosarcoma 12%
25. Heterografts 12%
26. Disclosure 11%
27. Hispanic Americans 10%
28. Clinical Trials 10%
29. Hormones 9%
30. Survival 9%
31. Tamoxifen 9%
32. Epithelial Cells 9%
33. Phosphorylation 9%
34. Fulvestrant 9%
35. Oncogenes 8%
36. N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 8%
37. Pharmaceutical Preparations 8%
38. Growth Factor Receptors 8%
39. Emotions 8%
40. Cell Line 7%
41. Child 7%
42. Biomarkers 7%
43. ribociclib 7%
44. Alpelisib 7%
45. Cell Movement 7%
46. Gefitinib 7%
47. Mitogen-Activated Protein Kinase Kinases 7%
48. NVP-BKM120 7%
49. Receptor Protein-Tyrosine Kinases 7%
50. Drug Therapy 7%
51. Antibodies 6%
52. Neoplasm Metastasis 6%
53. Colonoscopy 6%
54. MCF-7 Cells 6%
55. Carcinogenesis 6%
56. Proteins 6%
57. Herniorrhaphy 5%
58. Cancer Survivors 5%
59. Cell Proliferation 5%
60. Genes 5%
61. Down-Regulation 5%
62. Apoptosis 5%
63. Progression-Free Survival 5%
64. Cell Survival 5%
65. African Americans 5%
66. Inguinal Hernia 5%
67. Population 5%
68. IGF Type 1 Receptor 5%
69. Delivery of Health Care 5%
70. Income 5%
71. Nude Mice 5%
72. 3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid 5%